Clinical Trials Logo

Filter by:
NCT ID: NCT03449888 Terminated - Clinical trials for Veterans Referred to the St. Louis VAMC Stress Tes

Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome

ArmCrank
Start date: July 1, 2018
Phase:
Study type: Observational

This is a 5-year clinical trial to evaluate whether arm exercise electrocardiographic (ECG) stress testing without or with coronary artery calcium scoring (-/+ CAC) is non-inferior to treadmill ECG stress testing -/+ CAC and pharmacologic myocardial perfusion imaging as an initial evaluation to detect obstructive coronary artery disease, determined by cardiac computed tomographic angiography (CTA) and to predict clinical outcome, defined by a primary clinical endpoint of the composite of cardiovascular (CV) mortality, myocardial infarction, and 90-day post-stress test coronary artery revascularization and secondary clinical endpoints of all-cause mortality and CV mortality.

NCT ID: NCT03449524 Terminated - PAH Clinical Trials

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

PAH
Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.

NCT ID: NCT03449030 Terminated - Clinical trials for Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Start date: April 23, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.

NCT ID: NCT03448692 Terminated - Clinical trials for Focal Segmental Glomerulosclerosis (FSGS)

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

PODO
Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.

NCT ID: NCT03448367 Terminated - Diabetes Mellitus Clinical Trials

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

Start date: February 27, 2018
Phase:
Study type: Observational

This is a prospective, multi-center, non-randomized, single-arm, post-approval study of the FreeStyle Libre Flash Glucose Monitoring System intended to characterize the safety of the Libre Flash Glucose Monitoring System when used in pediatric patients with diabetes.

NCT ID: NCT03447769 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Canopy-A
Start date: March 16, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

NCT ID: NCT03447730 Terminated - Cirrhosis Clinical Trials

Safety, Tolerability and Pharmacodynamics of SYNB1020

Start date: March 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1b/2a, randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, and pharmacodynamics of SYNB1020 in hepatic insufficiency and cirrhosis patients with hyperammonemia, with dosing of the investigational medicinal product (IMP) administered in an inpatient unit and subsequent outpatient follow-up for SYNB1020 clearance in two study parts.

NCT ID: NCT03447639 Terminated - Clinical trials for Urinary Tract Infections

Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal

Start date: March 29, 2018
Phase: Phase 4
Study type: Interventional

Over the last decade, there has been great emphasis on reducing the incidence of hospital-acquired infections, including catheter-associated UTI (CAUTI). This study will evaluate the effectiveness of Betadine irrigation solution (2% povidone-iodine) instilled into the bladder immediately prior to indwelling catheter removal to decrease the risk of subsequent bacteriuria, leading to decreased rates of NHSN defined CAUTI.

NCT ID: NCT03447262 Terminated - Cystic Fibrosis Clinical Trials

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Start date: July 13, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.

NCT ID: NCT03446833 Terminated - Parkinson Disease Clinical Trials

LFP Beta aDBS Feasibility Study

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.